Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted

2025-10-10 17:18:54 ET

Shares of biopharmaceutical concern Monopar Therapeutics Inc. ( MNPR ) have had an absolutely massive surge in the past year after being left for dead with cash of $7.1 million and a market cap under $9 million. Its acquisition of Wilson disease candidate ALXN-1840 and a positive result from its imaging and dosimetry candidate MNPR-101-Zr are responsible for the remarkable turnaround. With an operating runway through YE26, an anticipated NDA filing for ALXN-1840 in early 2026, along with new and positive Street sponsorship, the surge in Monopar merited a deeper dive. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: